-

Karuna Therapeutics to Present at the Cowen and Company's 40th Annual Health Care Conference

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will present at the Cowen and Company's 40th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA. The Company is scheduled to present on Monday, March 2, 2020, at 11:20 a.m. ET.

A live webcast of the presentation will also be available on the investor relations page of the Karuna corporate website at investors.karunatx.com. After the live webcast, the event will remain archived on the Karuna website for 90 days.

About Karuna

Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders – which remain among the most disabling and potentially fatal disorders worldwide. Galvanized by the understanding that today’s neuropsychiatric and pain management patients deserve better, Karuna’s mission is to harness the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways that will advance the standard of care. For more information, please visit karunatx.com.

Contacts

Investors:
Chris Brinzey
Westwicke, an ICR Company
+1 339 970-2843
chris.brinzey@westwicke.com

Media:
Jenn Gordon
GlobalHealthPR
+1 202 587-2580
jgordon@globalhealthpr.com

Karuna Therapeutics, Inc.

NASDAQ:KRTX

Release Versions
$Cashtags

Contacts

Investors:
Chris Brinzey
Westwicke, an ICR Company
+1 339 970-2843
chris.brinzey@westwicke.com

Media:
Jenn Gordon
GlobalHealthPR
+1 202 587-2580
jgordon@globalhealthpr.com

More News From Karuna Therapeutics, Inc.

Karuna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will participate in a fireside chat at the virtual Goldman Sachs Annual Global Healthcare Conference...

Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, announced today that data from the Phase 2 clinical trial evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia will be presented at the American Society of Clinical Psychopharmacology (ASCP)...

Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (Nasdaq: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced financial results for the first quarter of 2020 and provided a general business update. “We are off to a strong start in 2020 and continue to make significant progress advancing our lead program,...
Back to Newsroom